Fact based stock research
Assertio Therapeutics (NasdaqGS:DEPO)

Assertio Therapeutics stock research in summary

Assertio Therapeutics shares have a market-typical stock price level. While they are good value, they are riskily financed, and show below average growth. We recommend evaluating whether the future of the company Assertio Therapeutics is typical for this industry which the market average price level of the shares suggests. If you believe that the future of the company is above average, that could be an argument for buying the shares and vice versa.

Latest Obermatt Ranks


Value Rank	64
Growth Rank	1
Safety Rank	8
Combined Rank	1

Country	USA
Industry	Pharmaceuticals
Index	NASDAQ, D.J. US Pharmaceutical
Size class	Small

September 6, 2019. Stock data may be delayed. Login to get the most recent research.

Add to Watchlist

Filter Similar Stocks

Similar Top 10

Google: Assertio Therapeutics

News	Videos
Wikipedia about Assertio Therapeutics	Management
Employee Satisfaction	Customer Satisfaction

Research History: Assertio Therapeutics

RESEARCH HISTORY	2016	2017	2018	2019
VALUE
VALUE	37	44	34	64
GROWTH
GROWTH	83	2	33	1
SAFETY
SAFETY	7	7	29	8
COMBINED
COMBINED	32	1	33	1

Last update of Combined Rank: 6-Sep-2019. Financial reporting date used for calculating ranks: 30-Jun-2019. Stock research history is based on the Obermatt Method. The higher the rank, the better Assertio Therapeutics is in the corresponding investment strategy.

Value Metrics in Detail

VALUE METRICS	2016	2017	2018	2019
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)	76	93	91	100
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)	6	8	10	27
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)	85	82	84	94
DIVIDEND YIELD
DIVIDEND YIELD	1	1	1	1
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE	37	44	34	64

Last update of Value Rank: 6-Sep-2019. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Assertio Therapeutics; except for dividend yield where the rank is higher, the higher the yield.

Growth Metrics in Detail

GROWTH METRICS	2016	2017	2018	2019
REVENUE GROWTH
REVENUE GROWTH	87	4	15	1
PROFIT GROWTH
PROFIT GROWTH	1	1	78	38
STOCK RETURNS
STOCK RETURNS	63	10	20	8
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH	83	2	33	1

Last update of Growth Rank: 30-Jun-2019. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Assertio Therapeutics.

Safety Metrics in Detail

SAFETY METRICS	2016	2017	2018	2019
LEVERAGE
LEVERAGE	8	8	10	1
REFINANCING
REFINANCING	6	1	10	2
LIQUIDITY
LIQUIDITY	24	23	64	62
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY	7	7	29	8

Last update of Safety Rank: 30-Aug-2019. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Assertio Therapeutics and the more cash is available to service its debt.

Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Assertio Therapeutics from September 6, 2019.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.